View Author
patient cancer study treatment group grade sarcoma imatinib survival cycle toxicity month therapy tissue response analysis phase tumor trial hyperthermia smoking chemotherapy pharmacokinetic table progression osi -7836 infusion lymphopenia research range eia-alone group tissue sarcoma es -285 disease level treatment group angiosarcoma lymphocyte activity -7836 tumour schedule article bone sarcoma group count effect european factor -285 sample death minute result oncol eia-alone event prognostic cyp 1a blood progression-free survival gemcitabine cancer research fatigue plasma smoker eortc agent 128 mg /m model centre metastatic association number resection american response rate phase i study toxicitie lymphoma breast
8 Most Recent Publications
|
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study
(Article)
Issels, R.D. Lindner, L.H. Vujaskovic, Z. Wessalowski, R. Jauch, K.W. Dürr, H.R. Ploner, F. Baur-Melnyk, A. Mansmann, U. Hiddemann, W. Blay, J-Y. Judson, I.R. Verweij, J. Wust, P. Reichardt, P. Schem, B.C. Abdel-Rahman, S. Daugaard, S. Salat, C. Wendtner, C.M. |
2010-06-01
|
|
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
(Article)
Ray-Coquard, I. Cropet, C. Guastalla, J.P. Bachelot, T. Perol, D. Chabaud, S. Hogendoorn, P.C.W. Cassier, P. Dufresne, A. Blay, J-Y. Glabbeke, M.M.B. van Sebban, C. Cesne, A. le Judson, I.R. Tredan, O. Verweij, J. Biron, P. Labidi, I. |
2009-07-01
|
|
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
(Article)
Baird, R.D. Kitzen, J.J.E.M. Kaye, S.B. Eskens, F.A.L.M. Workman, P. DeBono, J.S. Verweij, J. Clarke, P.A. Planting, A.S.T. Reade, S. Reid, A. Welsh, L. Lázaro, L.L. Las Heras, B. de Judson, I.R. |
2009-06-01
|
|
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
(Article)
Erp, N.P. van Gelderblom, H. Glabbeke, M.M.B. van Oosterom, A. van Verweij, J. Guchelaar, H.J. Debiec-Rychter, M. Peng, B. Blay, J-Y. Judson, I.R. |
2008-12-15
|
|
Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group
(Article)
Schlemmer, M. Reichardt, P. Verweij, J. Hartmann, J.T. Judson, I.R. Thyss, A. Hoogendoorn, P.C.W. Marreaud, S. Glabbeke, M.M.B. van Blay, J-Y. |
2008-11-01
|
|
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005
(Article)
Verweij, J. Casali, P.G. Kotasek, D. Cesne, A. le Reichard, P. Judson, I.R. Issels, R.D. Oosterom, A. van Glabbeke, M.M.B. van Blay, J-Y. |
2007-04-01
|
|
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
(Article)
Leahy, M. Ray-Coquard, I. Judson, I.R. Blay, J-Y. Verweij, J. Cesne, A. le Duffaud, F. Hogendoorn, P.C.W. Fowst, C. Balincourt, C. de Paola, E.D. di Glabbeke, M.M.B. van |
2007-01-01
|
|
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies
(Article)
Lee, C.P. Jonge, M.J.A. de Kaye, S.B. Judson, I.R. Verweij, J. O'Donnell, A.E. Schothorst, K.L. Hanwell, J. Chick, J.B. Brooimans, R.A. Adams, L.A. Drolet, D.W. Bono, J.S. de |
2006-05-01
|
